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Abstract
VALIDATION OF A WHOLE BLOOD SEROLOGY TEST FOR DIAGNOSING HELICOBACTER
PYLORI IN CHINESE PATIENTS.
Matthew S. Falk and Joseph J. Y. Sung. Department of Medicine and Therapeutics, Prince of Wales
Hospital, Chinese University of Hong Kong, Shatin, Hong Kong. (Sponsored by Matthew E. Cohen,
Department of Internal Medicine, Yale University School of Medicine).

Purpose To assess the accuracy of the FlexPack HP (Abbott Laboratory), a rapid whole blood mimunochromatographic serology test, for diagnosing Helicobacter pylori infection in Hong Kong Chinese
patients.

Methods Consecutive patients with dyspepsia presenting for endoscopic examination were recruited for
FlexPack HP testing. Those having received previous anti-// pylori therapy or those currently taking
antibiotics or acid-suppressive drugs were excluded. In addition to having the FlexPack HP test, all patients
were tested for H. pylori using histology, rapid urease test and a [13C] urea breath test. Patients were
considered to be infected with H. pylori when two or more of these three reference tests were positive.

Results One hundred patients were studied. The average age was 51 +/- 15 years (range 21-90 years),
55% of whom were female. Endoscopy revealed gastric ulcers in 5%, duodenal ulcers in 6%, gastric
erosions in 7%, gastric erythema in 20% and no apparent disease in 62%. Fifty-four (54%) of the patients
had H. pylori infection based on study definitions. FlexPack HP test characteristics were: sensitivity 82%
(95% CI: 73 - 88%), specificity 85% (95% CL 74 - 92%), positive predictive value 86% (95% CI: 77 93%) and negative predictive value 80% (95% CI: 70 - 86%). A faint line, interpreted as positive, was seen
in 15 (15%) of the FlexPack HP results. No invalid tests occurred as assessed by the control panel integral
to the FlexPack HP test.

Conclusion FlexPack HP was quick, convenient and accurate when used in a secondary care setting in
Hong Kong Chinese patients. This test may be useful for in-office H. pylori testing.
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Introduction
History
Our understanding of Helicobacter pylori and its role in peptic ulcer disease has
increased dramatically since its re-discovery in 1982 by Marshall and Warren who
isolated the bacterium from gastric biopsy specimens taken from patients with gastritis
(1). At that time, the micro-aerophilic, curved, spiral-shaped bacillus was named
Campylobacter pyloridis since it resembled other Campylobacters both morphologically

and in guanine/cytosine DNA content; later the name became Campylobacter pylori and
finally Helicobacter pylori (2, 3). This urease-producing organism exists in close
association with the epithelium of the gastric lumen. By 1984, Marshall and Warren had
presented and published this finding along with their discovery of the association of H.
pylori infection with both gastritis and peptic ulcer disease (4). Marshall even went so far

as to ingest the live organism purposely to demonstrate the acute effects of infection in an
effort to fulfill Koch's postulates (5).

Pathogenicity
The role of H. pylori as an important human pathogen became increasingly
defined over the following years. H. pylori is associated with chronic gastritis (6), and
gastric and duodenal ulcers (7, 8). More questionable studies have associated H. pylori
with gastric adenocarcinoma (9, 10) and gastric lymphoma (11, 12). H. pylori might
contribute to non-ulcer dyspepsia (13), migraine headaches (14), hyperemesis gravidarum
(15, 16), ischemic heart disease (17) or even childhood growth retardation (18), although
dubious and conflicting studies exist in some cases (19). In 1994 H. pylori was given
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grade I (i.e., definite) carcinogen status by the International Agency for Research on
Cancer (20).

Virulence
Virulence factors have been identified for H. pylori which may determine the
likelihood of developing disease and influence its severity. The two main virulence
factors identified to date are the toxins produced by the genes vacA (vacuolating
cytotoxin gene A) and cagA (cytotoxin associated gene A). Both vacA+ and ccigA +
strains are isolated more often from patients with peptic ulcers than from those without
ulcerative disease. The cagA+ strain is more often found in patients with gastric
adenocarcinoma than in those without the disease (21). The increased inflammation
caused by more virulent strains appears to be related to some of the gene products from
the cag pathogenicity island, a region with cagA as the marker sequence. Furthermore,
cytotoxicity of a strain is also affected by the vcicA genotype present, in that peptic
ulceration is associated with the strain’s vcicA signal sequence (21).
Although testing for the presence of the cagA marker sequence is the primary
viable diagnostic option predictive of disease at this time, the natural history of infection
caused by strains testing negative for cagA is not altogether clear. Determination of
virulence factors remains a research goal, at present, and has not yet been incorporated
into algorithms for the management of H. pylori (21).
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Transmission
H. pylori is a human pathogen with humans as the primary reservoir. However, a

mode of transmission has yet to be determined with certainty. Most evidence points to
both oral-oral and fecal-oral spread. Oral-oral spread is more likely the predominant
means of transmission in developed countries, whereas the fecal-oral route probably
accounts for most spread in developing countries (22). In addition, case reports exist of
iatrogenic transmission via flexible endoscopes that have contacted multiple patients
without proper disinfection (23). The housefly has been evaluated as a possible but
unproven vector for transmission (24). Transmission of H. pylori in Asian populations
was speculated to occur secondary to chopstick use, but this theory was rejected after
further investigation (25).

Epidemiology
H. pylori infection is the world’s most common human chronic bacterial

infection, with a world-wide prevalence of at least 50 to 60% (26, 27). However,
prevalence varies dramatically from region to region, particularly between developed
countries with rates between 25 to 50%, and developing countries with rates as high as 70
to 90% (26, 28).
A general review of studies on the epidemiology of H. pylori infection in China
determined the prevalence of infection to be 61% (29). A more specific study analyzing
65 Chinese counties found H. pylori seropositivity rates of 65% (range 28 - 94%) in
northern counties and 57% (range 29 - 96%) in southern counties (30). One study
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analyzing a specific southern China county found the prevalence of H. pylori infection to
be 80%. Interestingly, this study found a prevalence of only 58% in Hong Kong which
was comparable to a previous study (prevalence of 55%) (31, 32, 33). (Note that although
the prevalence for Hong Kong was lower than southern China, it is still significantly
higher than other developed countries.)
Furthermore, these rates are comparable to Chinese populations found in other
areas of Asia. A study carried out in Malaysia, a country with large Chinese and Indian
populations, found the prevalence in the Chinese cohort to be 49%. In contrast, the
prevalence of infection among the Malay and Indian populations was 16% and 62%,
respectively (34).

Risk Factors for Infection
The incidence of H. pylori infection among adults is low, estimated between 1%
per year in developed countries and 3% per year for developing countries (22). Childhood
appears to be the dominant time period for acquiring H. pylori (22, 26). Prevalence,
however, varies considerably among children in different regions; it appears that
acquisition is low in the children of developed countries, while in the developing world
this age group represents the major period of new infection (22). It has been hypothesized
that an ‘environmental pool’ of H. pylori exists to which children are exposed in
developing countries; in developed countries this source has either been eliminated or
children are not exposed to it. Either possibility is believed secondary to improvements in
sanitation, refrigeration and water purification. Consequently, adults more than 50 years
of age in developed countries maintain a high prevalence of infection (probably acquired
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in childhood), while prevalence is low among children in developed countries. The
present positive correlation between age and prevalence of infection is thought to be due
to a birth cohort effect (26).
Notable correlations do exist across all ages in which indirect relationships for
both socioeconomic status and education level and H. pylori infection have been shown;
other potential risk factors such as gender and alcohol use have been investigated, but
display no consistent relationship with prevalence. Interestingly, gastroenterologists and
endoscopists have been shown to display increased seropositivity for H. pylori (22).

Treatment
Despite mounting evidence supporting H. pylori's role in causing peptic ulcer
disease, many clinicians remained skeptical. It was not until February 1994 that the
National Institutes of Health convened a Consensus Development Conference Panel
which reviewed contemporary Helicobacter pylori research and concluded that peptic
ulcer disease was often an infections disease and should be treated as such.
Active H. pylori infection has been shown to be effectively treated by several
treatment protocols. The most successful in the U.S. consist of two weeks of acid
suppression combined with at least two antibiotics. The most popular combinations use a
proton pump inhibitor with either amoxicillin and a macrolide (typically clarithromycin)
or with a nitroimidazole (typically metronidazole) and a macrolide (35). These treatment
protocols cure H. pylori in 85 to 95% of patients enrolled in Western studies (36). Since
the outcome of therapy is probably dependent in part on antibiotic resistance, these rates
may differ in Asia due to the significantly higher levels of metronidazole resistance
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present there. For all strains of H. pylori, levels of metronidazole resistance as high as
50% have been reported in Hong Kong and Singapore (80 to 90% levels of resistance
were reported in India) (37).
In the future, therapy for H. pylori may consist of vaccination. Current efforts in
mice have succeeded in producing vaccines that not only prevent infection, but also cure
preexistent H. pylori infection. However, these vaccines, which use a H. pylori urease,
cannot yet be applied to humans since they require an adjuvant detrimental to humans,
such as cholera toxin. A more efficacious vaccine may result from efforts to utilize H.
pylori outer membrane proteins (OMPs), such as porins, to produce an effective immune

response (36).

Eradication
Although H. pylori is the most common chronic bacterial infection in humans
with definite links to gastrointestinal pathology, most infected people never display
clinical signs or symptoms of disease (27). Consequently, arguments have been made for
and against widespread vaccination or eradication of this organism and whether
eradication would be cost effective (38, 39). Some studies have even suggested a
beneficial role for H. pylori in protecting against gastroesophageal reflux disease (GERD)
(40, 41) and possibly a secondary protection from the GERD-induced esophageal cancer.
Yet, in patients with PUD, eradication of H. pylori decreases the recurrence rate of PUD
to 4%, from 80% (or 25% if on long-term histamine-2 (H2) receptor blockers).
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Diagnostic Tests for Infection
As awareness of the role of H. pylori in gastroduodenal diseases has increased,
many patients have sought testing and treatment from their primary care physicians.
Invasive biopsy-based tests, including culture, histology and the rapid urease test, are
effective in diagnosing H. pylori infection. However, considerable investments in
facilities, equipment, expertise and time are required to perform these tests. Invasive tests
are not a practical option for the primary care setting in which testing is performed at the
site.
Non-invasive tests are attractive for this setting in that they do not have many of
these requirements. Additionally, non-invasive tests eliminate the potential for sampling
error of the biopsy-based tests due to the patchy distribution of H. pylori in some patients.
In fact, screening young dyspeptic patients for H. pylori by non-invasive tests such as
serology has been shown to reduce the need for endoscopy by up to 30% without missing
significant disease in Western countries (42, 43, 44) and economic modeling suggests this
strategy is cost effective (45). Still, conventional non-invasive tests such as serum
enzyme-linked immunosorbent assays (ELISA) and urea breath tests also require
laboratory support which itself is not widely available in primary care settings.
Commercial rapid whole blood tests for H. pylori have been introduced in recent
years. These tests do not require separation of serum, and results are available within
minutes without the need of laboratory assistance. It is important to note that these near¬
patient rapid whole blood tests, unlike ELISA assays, are qualitative tests. Still,
preliminary studies found these commercial kits may be as accurate as laboratory-based
serology tests (46, 47, 48), when tested in Western populations.

Due to the antigenic heterogeneity of H. pylori, the performance of commercial
serology tests varies considerably among different populations (49, 50). To date, most
published data have been based on Western populations (46, 47, 48, 51, 52, 53, 54, 55,
56, 57, 58). Whether these results can be reproduced in Asians remains unknown.
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Statement of Purpose and Hypothesis
The aim of this study was to assess the performance of the rapid whole blood test,
FlexPack HP (Abbott Laboratories, North Chicago, Illinois), in Chinese patients with
dyspepsia. It was our hypothesis that the Abbott FlexPack HP Test for IgG antibodies to
Helicobacter pylori infection in whole blood is accurate for diagnosing H. pylori

infection in Chinese (specifically Hong Kong Chinese) patients with clinical signs and
symptoms of upper gastrointestinal tract disease.

-
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Materials and Methods
Location of Study
This study was carried out at the Prince of Wales Hospital in Hong Kong, China.
Prince of Wales Hospital, the first fully air-conditioned Government hospital in Hong
Kong, was officially opened in 1984. Located in the city center of Shatin, it is an acute
general hospital as well as the teaching hospital of the Medical Faculty of the Chinese
University of Hong Kong. With more than 1,400 beds and a total workforce of over
4,000, it is the regional hospital of the Eastern New Territories serving the population of
Shatin, Tai Po, Northern New Territories, Sai Kung and the outlying islands (59).

Protocol
Consecutive patients about to undergo esophagogastroduodenoscopy to evaluate
dyspepsia were considered for enrollment between June 17, 1997 and August 6, 1997.
My goal was to enlist 100 patients, a sample size selected arbitrarily. Exclusion criteria
were age less than 18 years, previous treatment for H. pylori, previous gastric surgery,
and current use of antibiotics, proton pump inhibitors, or H2 receptor blockers. Informed
verbal consent was obtained from all subjects by research nurses. All patients underwent
endoscopy (Olympus XQ-200; Olympus, Tokyo, Japan) with biopsy in the Endoscopy
Center at Prince of Wales Hospital, performed by the center’s staff physicians. Three
antral and two body biopsy samples were taken from the stomach: one antral biopsy was
used for rapid urease testing and the remaining four biopsies were sent for histological
evaluation. The rapid urease test (CLOtest, Delta West, Bentley, Australia) was
performed at room temperature and was considered negative if no colorimetric change
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occurred within 24 hours.

Specimens destined for histologic inspection were placed in

10% formalin, transported to the hospital’s pathology department and subsequently
stained with hematoxylin and eosin.

The hospital’s staff pathologists detennined

histological diagnosis.
All patients also underwent f13C] urea breath testing (UBT) at least two hours
after endoscopy.

UBT’s were perfonned either by a research nurse or by myself; the

laboratory analyzed all results. Following a previously described method (60) the fasting
patient first drank a test meal consisting of a 200 ml concentrated citrate solution to delay
gastric emptying.

Following a two-minute delay, three baseline breath samples were

collected. Samples were obtained by having the patient blow through a straw resting
inside of a 10ml test tube. The straw was slowly withdrawn from the tube over
approximately a four-second period until a blush of condensation appeared, immediately
after which the tube was capped. After an eight-minute delay, the patient swallowed a
lOOmg [l3C] urea tablet (Cambridge Isotope Laboratories Inc., Andover, Massachusetts)
dissolved in 25ml of water, followed by a 25ml drink of water alone. The patient then
performed one minute of exercise including deep waist bends to encourage sample
mixing.

After 30 minutes, three additional breath samples were obtained from the

patients in the previously described fashion. All samples were covered with Parafilm
until analyzed via mass spectrometry (Europa scientific 20:20 Isotope Ratio Mass
Spectrometer with a RoboPrep G Automatic Breath Sampler). The
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C/ C ratio of the

sample was calculated by the computer against the known isotopic ratio of the reference
gas.

The l3C/12C isotopic ratios were reported in the per ml format: delta 13C/ml =

(((l3C/12C sample)-!) X IOOO)/(13C/l2C Standard).

Excess l3C was calculated as the
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difference between the baseline delta l3C and 30 minute delta l3C (30-minute delta l3C
baseline l3C).

Values greater than or equal to 3.5 were considered to be positive.

Patients with concordant histology and CLOtest results, but a discordant UBT result
returned for a second UBT which was used as the final UBT result in all cases.
Patients were tested for H. pylori on the day of their endoscopy using the
FlexPack HP rapid whole blood serology test kit (manufactured by SmithKline
Diagnostics, Inc. for Abbott Laboratories, Abbott Park, Illinois). I performed all FlexPack
HP tests. The FlexPack HP test incorporates high molecular weight cell-associated
proteins as the antigen to detect H. pylori-specific IgG antibodies in whole blood.
FlexPack HP test cards ready for study were kept at room temperature (no more than 30
days), opened within minutes of use and were prepared according to the manufacturer’s
specifications. After venipuncture, blood was immediately transferred from the syringe
into EDTA and soybean extract-coated mini-pipets included in the test kit and directly
applied to the appropriate chromatography column on the prepared test card. Following
the flow of the sample through this initial column to its termination point, the test card
was closed and the time was noted. After exactly four minutes the results were read in the
card’s test window. Within the test window the appearance of two distinct lines was
treated as positive, a single control line represented a negative result, and the absence of
any line indicated an invalid test. Any trace of a line in the expected positive position was
regarded as a positive result per product instructions. I read all the rapid whole blood test
results without knowledge of the endoscopy findings, or results from other H. pylori tests.
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Data Analysis
The “gold standard” used to determine H. pylori infection was defined prior to
analysis as positive results of at least two of the three reference tests performed to
diagnose H. pylori infection (histology, CLOtest and UBT).

I calculated sensitivity,

specificity and positive and negative predictive values for the FlexPack HP with 95%
confidence intervals using formulas created within Microsoft Excel 97 (Microsoft,
Redmond, Washington) and using the Java based internet site “2-way Contingency Table
Analysis,” (61). Unpaired Ttests (mean comparison) and Z-tests (proportion comparison)
were performed using the internet sites “r test: Independent Groups,”(62) and “WebStatProportions (p statistics): Two sample,” respectively (63). A P value of 0.05 was
considered statistically significant. Data are summarized as mean +/- standard deviation.
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Results
Patient Characteristics
Characteristics of 100 patients from Hong Kong undergoing upper GI tract
endoscopy for dyspepsia are displayed in Table 1. One hundred patients (55 female, 45
male) were studied. The patients' mean age was 51 +/- 15 years (range, 21 to 90 years).
Fifty-eight patients (58%) were older than 45 years of age. Seventeen (17%) patients had
a history of peptic ulcer disease. At esophagogastroduodenoscopy, five (5%) patients had
gastric ulcers, six (6%) had duodenal ulcers, seven (7%) had gastric erosions and 20
(20%) had gastric erythema. In the remaining 62 patients, no endoscopically apparent
disease was found. No patients had duodenitis or duodenal erosions.
Characteristics of H. pylori prevalence in the 100 patients studied are given in
Table 2. Fifty-four (54%) patients were confirmed to be H. pylori positive based on at
least two positive results among the reference tests (rapid urease test, histology, and [l3C]
urea breath test). The H. pylori-positive group had a mean age (51 +/- 15 years) similar to
the H. pylori-negative group (52 +/- 16). There was no statistically significant difference
in prevalence of infection between men and women (55% vs. 53%, respectively [P =
NS]).
The prevalence of H. pylori was highest among the six patients with duodenal
ulcers and the five patients with gastric ulcers (83% and 80% respectively). The
prevalence among the 20 patients with gastric erythema was 60%. Thirty of the 62
patients with no apparent disease (49%) were H. pylori positive and three of seven
patients (43%) with gastric erosions were positive for H. pylori. Note that the prevalence
of H. pylori in the group with ulcers, nine of eleven patients (82%), was significantly
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different from the prevalence in the group without ulcers, 45 of 89 patients (51%) (P =
0.05).

Diagnosis of H. pylori Infection - Reference Panel Analysis
The relationship between reference test and FlexPack HP test results in each of
the 100 patients are presented in Table 3. Concordance of all test results (including the
FlexPack HP) occurred in 74 of the 100 patients. Reference tests alone were concordant
in 89 of the 100 patients; in 11 patients, reference tests were discordant.
Each reference test method was discordantly positive or negative in at least one
patient. Three of the 54 “//. /^/on-positive” patients tested negative for infection by
histology, two patients by UBT and one patient by CLOtest. Three of the 46 “//. pylorinegative” patients tested positive for infection by UBT, and two by histology.

Diagnosis of H. pylori Infection - FlexPack HP Test Performance
The sensitivity, specificity, positive and negative predictive values for the
FlexPack HP are 82%, 85%, 86% and 80% respectively (see Table 4). Also shown on
Table 4 are values for FlexPack HP’s performance in the age groups less than or equal to
45, greater than 45, less than or equal to 65 and greater than 65 years of age; no
statistically significant differences occurred in any of the characteristics between the age
groups. Poor readability, manifested as faintly positive results, occurred in 15 FlexPack
HP observations (15%). All tests were valid based on performance of built-in positive
controls. However, one of the 51 positive FlexPack HP observations and three of the 49
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negative observations displayed faint positive control lines. None of the tests with faint
positive control lines displayed discordant results from the defined gold standard.
Among the nine patients with H. pv/or/'-associated peptic ulcers, false-negative
serology was encountered in two of the four (50%) patients with gastric ulceration. No
false-negative FlexPack FIP results occurred in the five patients with H. py/oz-z-associated
duodenal ulceration or in the three patients with H. pylori-associated gastric erosion.
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Discussion
In 1994, the National Institutes of Health Consensus Development Panel on H.
pylori recommended eradication of H. pylori infection in all infected patients with active

peptic ulcer disease or with a history of PUD and on maintenance acid suppression. Tests
for diagnosing Helicobacter pylori infection which are simple, accurate and rapid are
needed in the near-patient setting to facilitate the diagnosis and treatment of H. pylori. In
fact, the American Gastroenterological Association’s 1998 medical position statement for
evaluation of dyspepsia specifically recommended that “a locally validated noninvasive
H. pylori test (e.g., serology or urea breath test) is undertaken to detennine if the patient

is infected” for patients under 46 years of age without alarm features or previous
investigations

(64).

A

European

H.

pylori

study

group

developed

similar

recommendations (65).
Guidelines for the Asian Pacific region, following the initiatives of the West, were
formulated in

1997.

Unique characteristics of this population

include the high

background prevalence of infection, high rates of gastric cancer, and limited resources in
the medical community. Non-endoscopic methods were deemed acceptable for this
region as diagnostic tests for H. pylori infection, including the UBT or a locally validated
antibody test (66). Clinicians in Hong Kong, being members of this region, played a
major role in formulating these guidelines.
In previous studies, prevalence of H. pylori infection in Hong Kong was 55
58%, a rate comparable to the value of 54% found in the present analysis. Although Hong
Kong is a developed country, its population displays a high H. pylori prevalence, even in
younger age groups. For example, the 21 to 30 year age group in previous studies
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displayed a prevalence of 53%, while our study determined a value of 52% for those no
older than 45 years of age (31, 32, 33). (The 21 to 30 year age group in our study
consisted of only eight members, however, 50% were positive for H. pylori infection.)
The analysis of H. pylori prevalence in relation to endoscopic diagnoses in this
study is also similar to previous studies. While the number of cases are low in each
diagnostic category (see Table 1), values of 48%, 80% and 83% prevalence were found
for no apparent disease, gastric ulcer and duodenal ulcer patients, respectively. These
values compare to those from native Southern Chinese patients of 45%, 76% and 75%,
respectively. In studies highlighting Hong Kong Chinese, duodenal ulcer was noted to be
positive for H. pylori in excess of 90% (67).
Considering the extent of the problem of H. pylori infection in the Hong Kong
Chinese population, a comprehensive plan was required to diagnose and treat positive
cases. As noted earlier, an antibody test was deemed acceptable for this population if
locally validated. Most serology studies prior to this, however, were earned out in
Western populations and few had previously assessed whole blood serology tests.
Subsequent studies have shown commercial rapid whole blood serology tests to be
adequately accurate and potentially useful for in-office H. pylori testing if clinicians are
aware of the limitations of the tests (68, 69). Clinicians must remember that these tests
can only indicate the presence of specific IgG antibodies to H. pylori, but do not
distinguish between current and past H. pylori infection; furthermore, a negative test may
indicate that H. pylori antibodies either are not present or are present at levels too low for
detection, as may be the case early in infection. Although these near-patient, rapid whole

19

blood tests appeared appropriate for the needs of the Hong Kong Chinese population,
they required local validation.
This is the first analysis of a rapid whole blood test for H. pylori in the Hong
Kong Chinese population. In this study, the overall performance of the FlexPack HP test
in Hong Kong Chinese patients was comparable to Western results for other commercial
serology kits. Our study determined a sensitivity of 82% (Cl 73 - 88%) and a specificity
of 85% (Cl 74 - 92%) for the FlexPack HP which compares favorably to sensitivities of
83 to 96% and specificities of 70 to 93% from the West (46, 47, 48, 51, 52, 53, 54, 55, 56,
57, 58).
Previously,

discrepancies between

Western

and Asian populations

in

the

performance of commercial serology tests for H. pylori were reported (49, 58, 70). A
study from Thailand showed that a commercial ELISA (Pylori Stat; BioWhittaker,
Walkerville, Maryland) was inferior to an ELISA developed from local H. pylori strains
(49). Prior experience at Prince of Wales Hospital with commercial ELISAs in a group of
Chinese patients was also disappointing (70). The performance of another rapid whole
blood serology test, the Helisal One-Step, was recently evaluated between two groups of
European and South Asian patients in a study from Britain (58). The authors reported
unexpectedly poor results in Asian patients (sensitivity, 79 to 81% versus 93 to 96%;
specificity, 42 to 50% versus 57 to 64%).
The reasons for these earlier discrepant results are unclear. Poor sensitivity in
prior comparisons is possible if antibody is absent, in a concentration too low to detect, or
non-reactive to the antigen in the assay. In earlier studies, poor sensitivity may be
accounted for by the considerable antigenic heterogeneity of H. pylori. By using bacterial
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isolates and sera from different continents, Hook-Nikanne et al. demonstrated that
antigens prepared from individual bacterial strains obtained from North America and
China were not sensitive enough for serological detection of H. pylori in a heterogeneous
population (50). This phenomenon may be overcome by using pools of bacterial strains
obtained from different ethnic groups. If the patented antigen utilized in the FlexPack HP,
high molecular weight cell-associated proteins (HM-CAP™), is of the pooled type, it
could explain the comparable sensitivity realized in this study.
Our study also demonstrated specificity for FlexPack HP comparable to Western
analyses. Poor specificity in previous comparisons may be accounted for by the high
carriage of other cross-reacting intestinal pathogens in developing countries, such as
Campylobacter species, which may produce false-positive serological results (46). This
problem is less likely with FlexPack HP since it has been previously shown to have no
cross

reactivity

with

a

number

of bacteria,

including

Campylobacter jejuni,

Campylobacter fetus, Campylobacter coli, Escherichia coli, and Helicobacter mustalae
(71). An alternate explanation involves the inadvertent use of antibiotics for respiratory
and intestinal infections in the community which may inhibit or even eradicate H. pylori.
Since antibody can persist in serum for months after eradication, serological results may
be falsely-positive after eradication and contribute to decreased test specificity. Previous
studies may not have controlled for this possibility. The present study excluded patients
previously treated for H. pylori or currently using antibiotics.
In North America and Europe, the test-and-treat strategy has been adopted for the
management of dyspepsia (64, 65). Serology, being more widely accessible than the urea
breath test, is likely to become more popular for this purpose. Our study found overall
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sensitivity and specificity to be similar to that for series carried out in the West. A study
in a larger population of Hong Kong Chinese less than 45 years of age may be
appropriate before this serology kit is used in test-and-treat protocols in this age group.
Furthermore, our analysis found that 50% of H. /?v/on'-associated gastric ulcers (two of
four gastric ulcer patients, or two of nine [22%] peptic ulcer patients overall) would have
been missed had endoscopy been withheld in these patients with negative rapid whole
blood serology tests. Lastly, the risk of missing young patients with gastric cancer has not
yet been considered.
In conclusion, the FlexPack HP is quick and convenient to use and performed
adequately in a secondary care setting in Hong Kong Chinese patients. This test may be
useful for in-office H. pylori testing if clinicians are aware of the limitations of the test.
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Table 1. Characteristics of 100 Consecutive Patients From Hong Kong Who Had Esophagogastroduodenoscopy to Evaluate Dyspepsia
Age
Gender
Female
Male
Prior ulcer disease
Endoscopic diagnosis
No apparent disease
Gastric erythema
Gastric erosion
Duodenal ulcer
Gastric Ulcer
Mean +/- standard deviation

51 +/- 15 years a
55%
45%
17%
62%
20%
7%
6%
5%
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Table 2. Characteristics of H. pylori Prevalence in 100 Patients From Hong Kong Who
Had Esophagogastroduodenoscopy to Evaluate Dyspepsia "
Age
H. pylori-positive group (n = 54)

51 +/- 15 years h

H. pylori- negative group (n = 46)

52 +/- 16 years

Overall H. pylori prevalence

54%

H. pylori prevalence for endoscopic diagnosis

Duodenal ulcer (n = 5)

83%

Gastric ulcer (n = 4)

80%

Gastric erythema (n = 12)

60%

Gastric erosion (n = 3)

43%

No apparent disease (n = 30)

48%

“ Patients were confirmed to be H. pylori positive based on at least two positive results among the
reference tests: rapid urease test, histology, and [1 3C] urea breath test.
h Mean +/- standard deviation
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Table 3. Relationship Between Reference Test Results and FlexPack HP Results Among 100
Patients With Dyspepsia From Hong Kong “

0
FlexPack HP Positive
FlexPack HP Negative
Total

6
35
41

Number of Reference Tests Positive
1
2
3
1
4
5

5
1
6

39
9
48

n Patients were confirmed to be H. pylori positive based on at least two positive results among the
reference tests (rapid urease test, histology, and [l3C] urea breath test).
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Table 4. Performance Characteristics of FlexPack HP, a Rapid Whole Blood Serology Test For
H. pylori Infection, Among 100 Patients With Dyspepsia From Hong Kong
Predictive value (% [Cl])
Group

Number

Sensitivity

Specificity

(% [Cl])a

(% [Cl])

Positive

Negative

Overall

100

82 (73 - 88)

85 (74 - 92)

86 (77 - 93)

80(70 - 86)

<= 45 years

42

73 (57 - 82)

85 (67 - 96)

84 ( 66 - 95)

74(59 - 83)

> 45 years

58

88 (76 - 95)

85 (70 - 93)

88 (76 - 95)

85 (70 - 93)

<= 65 years

82

80 (71 - 87)

83 (71 - 92)

86 ( 76 - 93)

77(65 - 85)

> 65 years

18

88 (56 - 99)

90 (65 - 99)

88 (56 - 99)

90(65 - 99)

" Cl = confidence interval
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